Skip to main content
main-content

Oncology conference coverage

medwireNews@ESMO2016

18-10-2016 | Gynaecological cancer | News | Article

Editor's pick

Niraparib maintenance ‘warranted’ for platinum-sensitive recurrent ovarian cancer

ENGOT-OV16/NOVA trial results support the use of maintenance treatment with niraparib for platinum-sensitive recurrent ovarian cancer, in both patients with and without a germline BRCA mutation.

Source:

N Engl J Med 2016; Advance online publication;  ESMO 2016; Copenhagen, Denmark

More ESMO 2016 coverage

09-11-2016 | Non-small-cell lung cancer | News | Article

Ceritinib outperforms chemotherapy in pretreated ALK-positive NSCLC

The ASCEND-5 trial results establish ceritinib as a valid option for pretreated non-small-cell lung cancer patients harboring anaplastic lymphoma kinase translocations.

07-11-2016 | Non-small-cell lung cancer | News | Article

Atezolizumab prolongs advanced NSCLC overall survival

The programmed death-ligand 1 directed antibody atezolizumab confers an overall survival advantage relative to docetaxel in previously treated patients with locally advanced or metastatic non-small-cell lung cancer, indicate phase III trial findings.

03-11-2016 | Melanoma | News | Article

Melanoma survival extension with adjuvant ipilimumab comes at toxicity cost

Updated phase III trial results show that ipilimumab treatment improves overall survival and distant metastasis-free survival in stage III melanoma patients who have undergone complete resection, but with increased toxicity relative to placebo.

medwireNews@ECC2015

23-10-2015 | Non-small-cell lung cancer | Article

Editor's pick

Nivolumab vs docetaxel updated results for nonsquamous, squamous NSCLC

Follow-up results from two trials of the programmed death 1 receptor inhibitor nivolumab versus docetaxel in patients with advanced non-small cell lung cancer were reported at a proffered paper session held at the European Cancer Congress in Vienna, Austria.

Source:

ECC 2015; Vienna, Austria

20-10-2015 | Lung cancer | News | Article

Early trial results in lung cancer

Results from early phase trials investigating different therapeutic agents in lung cancer patients were presented during the third Presidential Session at the European Cancer Congress in Vienna, Austria. Here we summarise two studies reported at the session.

16-10-2015 | Melanoma | News | Article

PD-1 blockade in advanced melanoma

The safety and efficacy of the programmed death 1 inhibitors nivolumab and pembrolizumab in patients with melanoma formed a key part of the Melanoma and Skin Cancer proffered paper session at the European Cancer Congress in Vienna, Austria. This report summarises two presentations from the session.

07-10-2015 | Oncology | News | Article

Everolimus, 177Lu-dotatate extend neuroendocrine tumour PFS

Positive progression-free survival results from the RADIANT-4 and NETTER-1 trials extend the armamentarium for physicians treating patients with neuroendocrine tumours.

07-10-2015 | Melanoma | News | Article

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

Updated results from the COMBI-v trial show significantly improved overall and progression-free survival with first-line dabrafenib plus trametinib compared with vemurafenib in patients with advanced melanoma.

07-10-2015 | Oncology | News | Article

Brain metastases evolve ‘clinically actionable’ mutations

Brain metastatic disease shows branched evolution from the primary tumour, suggest preliminary findings from the largest massively parallel sequencing study of paired samples performed so far.

06-10-2015 | Kidney cancer | News | Article

Cabozantinib, nivolumab ‘bring hope’ for advanced RCC patients

Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.

05-10-2015 | Melanoma | News | Article

Nivolumab, ipilimumab duo effective in poor prognosis advanced melanoma patients

Subgroups of advanced melanoma patients with a poor prognosis derive a progression-free survival benefit from the combination of nivolumab and ipilimumab, according to research presented at the European Cancer Congress in Vienna, Austria.

medwireNews@ASCO2015

02-06-2015 | Oncology | News | Article

Editor's pick

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Two phase III trials published in The New England Journal of Medicine support the use of nivolumab in patients with treatment-naïve metastatic melanoma and in those with squamous non-small-cell lung cancer who have failed first-line chemotherapy.

Source:

N Engl J Med 2015; Advance online publication

08-06-2015 | Oncology | News | Article

Ibrutinib shows promise in CLL/SLL

The addition of ibrutinib to bendamustine and rituximab significantly prolongs progression-free survival in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma, according to the HELIOS trial.

05-06-2015 | Breast cancer | News | Article

PALOMA3 supports palbociclib use in advanced breast cancer

Advanced breast cancer patients who have failed prior endocrine treatment may receive a progression-free survival benefit if palbociclib is added to fulvestrant, a phase III trial indicates.

04-06-2015 | Oncology | News | Article

Elotuzumab boosts response in relapsed, refractory multiple myeloma

Addition of the immunostimulatory antibody elotuzumab to the combination of lenalidomide and dexamethasone improves progression-free survival and the overall response rate in patients with relapsed or refractory multiple myeloma, research suggests.

image credits